Dr. Weber on Growing Costs With Triplet and Four-Drug Regimens in Melanoma

Video

In Partnership With:

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Weber attests to the advances that have been made in triplet and four-drug regimens, discussing a clinical trial combining ipilimumab (Yervoy) and nivolumab (Opdivo) with a histone deacetylase inhibitor as an example. It is possible that flipping the dose levels and adjusting the schedule so there is no prohibitive toxicity will lead to the implementation of triplets in immunotherapy.

According to Weber, though trials such as these appear promising, there are financial toxicities with these systemic therapies that pose a major deterrent to these trials’ progress and application in mainstream medicine.

Though Weber sheds light on the potential of these trials, he also acknowledges the increasing costs of drugs, which could lead to greater issues in healthcare in the future.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine